Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03189875 · ClinicalTrials.gov registry record
Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 830
- Enrollment target
NCT03189875 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 830 participants.
The verdict
NCT03189875 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 830 participants
- Enrollment target
Study Summary
SPOCS is an international, multicenter, prospective observational cohort study with bi-annual study visits over a 3-year follow-up designed to systematically describe the comprehensive SLE patient-journey regarding clinical features, disease progression and treatment patterns, SLE outcomes, health status assessments (PROs), and health care resource utilization (HCRU) in a general population of moderate-to-severe SLE patients.
Interventions
- OTHER Standard of Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 830 participants |
| Start Date | 2017-06-28 |
| Est. Completion | 2022-11-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03189875
The ClinicalTrials.gov registry entry for NCT03189875 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 830 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Standard of Care is the first listed.
NCT03189875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03189875 about?
NCT03189875 is a clinical study titled "Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)". SPOCS is an international, multicenter, prospective observational cohort study with bi-annual study visits over a 3-year follow-up designed to systematically describe the comprehensive SLE patient-journey regarding clinical features, disease progression and treatment patterns, SLE outcomes, health s...
What is the current status of trial NCT03189875?
This trial is currently completed. The enrollment target is 830 participants. The study started on 2017-06-28. Estimated completion is 2022-11-18.
What interventions are being tested in trial NCT03189875?
The interventions under investigation include: Standard of Care (OTHER).
Who is sponsoring clinical trial NCT03189875?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.